Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report.
Lenalidomide
Mucinous adenocarcinoma
Multiple myeloma
Peritoneal dissemination
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
received:
19
12
2023
accepted:
04
02
2024
medline:
7
2
2024
pubmed:
7
2
2024
entrez:
7
2
2024
Statut:
epublish
Résumé
Concomitant multiple myeloma (MM) and other primary malignancies is rare. Therefore, the treatment outcomes of patients with these conditions have not been well discussed. Lenalidomide is an oral thalidomide analog drug used for MM. Recently, the antitumor effect of lenalidomide has been gaining attention, and lenalidomide has been applied for managing solid tumors. The current case showed the treatment course of a patient treated with lenalidomide for concomitant MM and colon cancer with peritoneal dissemination. A 74-year-old female patient receiving treatment for MM was diagnosed with mucinous adenocarcinoma of the transverse colon. The patient was clinically diagnosed with stage IIIC T4aN2M0 disease. Subsequently, laparoscopic colectomy with lymph node dissection was planned. However, intraperitoneal observation revealed peritoneal dissemination that had sporadically and widely spread. Therefore, palliative partial colectomy was performed to prevent future hemorrhage or obstruction. The patient was discharged on the 10th postoperative day without postoperative complication. Based on the patient's preference, lenalidomide was continually administered for MM without systemic chemotherapy. The patient survived for > 36 months without any signs of tumor progression. The current case first showed the treatment course of concomitant MM and colon cancer. The antitumor effect of lenalidomide can possibly contribute to 3-year progression-free survival in patients with mucinous adenocarcinoma of the colon with peritoneal dissemination.
Sections du résumé
BACKGROUND
BACKGROUND
Concomitant multiple myeloma (MM) and other primary malignancies is rare. Therefore, the treatment outcomes of patients with these conditions have not been well discussed. Lenalidomide is an oral thalidomide analog drug used for MM. Recently, the antitumor effect of lenalidomide has been gaining attention, and lenalidomide has been applied for managing solid tumors. The current case showed the treatment course of a patient treated with lenalidomide for concomitant MM and colon cancer with peritoneal dissemination.
CASE PRESENTATION
METHODS
A 74-year-old female patient receiving treatment for MM was diagnosed with mucinous adenocarcinoma of the transverse colon. The patient was clinically diagnosed with stage IIIC T4aN2M0 disease. Subsequently, laparoscopic colectomy with lymph node dissection was planned. However, intraperitoneal observation revealed peritoneal dissemination that had sporadically and widely spread. Therefore, palliative partial colectomy was performed to prevent future hemorrhage or obstruction. The patient was discharged on the 10th postoperative day without postoperative complication. Based on the patient's preference, lenalidomide was continually administered for MM without systemic chemotherapy. The patient survived for > 36 months without any signs of tumor progression.
CONCLUSION
CONCLUSIONS
The current case first showed the treatment course of concomitant MM and colon cancer. The antitumor effect of lenalidomide can possibly contribute to 3-year progression-free survival in patients with mucinous adenocarcinoma of the colon with peritoneal dissemination.
Identifiants
pubmed: 38324080
doi: 10.1186/s40792-024-01838-5
pii: 10.1186/s40792-024-01838-5
doi:
Types de publication
Journal Article
Langues
eng
Pagination
34Informations de copyright
© 2024. The Author(s).
Références
Ji SH, Park JO, Lee J, Oh MJ, Lim DH, Park BB, et al. Three cases of synchronous solid tumor and multiple myeloma. Cancer Res Treat. 2004;36:338–40. https://doi.org/10.4143/crt.2004.36.5.338 .
doi: 10.4143/crt.2004.36.5.338
pubmed: 20368825
pmcid: 2843872
Dong HH, Li J, Kang L, Wei Q, Li Y. Simultaneous multiple myeloma and non-small cell lung carcinoma: a case report and review of the literature. Oncol Lett. 2022;23:195. https://doi.org/10.3892/ol.2022.13315 .
doi: 10.3892/ol.2022.13315
pubmed: 35572492
pmcid: 9100747
Segler A, Tsimberidou AM. Lenalidomide in solid tumors. Cancer Chemother Pharmacol. 2012;69:1393–406. https://doi.org/10.1007/s00280-012-1874-2 .
doi: 10.1007/s00280-012-1874-2
pubmed: 22584909
Fadel MG, Malietzis G, Constantinides V, Pellino G, Tekkis P, Kontovounisios C. Clinicopathological factors and survival outcomes of signet-ring cell and mucinous carcinoma versus adenocarcinoma of the colon and rectum: a systematic review and meta-analysis. Discov Oncol. 2021;12:5. https://doi.org/10.1007/s12672-021-00398-6 .
doi: 10.1007/s12672-021-00398-6
pubmed: 35201441
pmcid: 8762524
Huang A, Yang Y, Shi JY, Li YK, Xu JX, Cheng Y, et al. Mucinous adenocarcinoma: a unique clinicopathological subtype in colorectal cancer. World J Gastrointest Surg. 2021;13:1567–83. https://doi.org/10.4240/wjgs.v13.i12.1567 .
doi: 10.4240/wjgs.v13.i12.1567
pubmed: 35070064
pmcid: 8727185
Park JS, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, et al. Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer. Medicine (Baltimore). 2015;94: e658. https://doi.org/10.1097/MD.0000000000000658 .
doi: 10.1097/MD.0000000000000658
pubmed: 25881840
Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108:1432–9. https://doi.org/10.1038/bjc.2013.82 .
doi: 10.1038/bjc.2013.82
pubmed: 23511564
pmcid: 3629432
Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17:1709–19. https://doi.org/10.1016/S1470-2045(16)30500-9 .
doi: 10.1016/S1470-2045(16)30500-9
pubmed: 27743922
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7. https://doi.org/10.1200/JCO.2011.37.1039 .
doi: 10.1200/JCO.2011.37.1039
pubmed: 22162570
Crane E, List A. Immunomodulatory drugs. Cancer Investig. 2005;23:625–34. https://doi.org/10.1080/07357900500283101 .
doi: 10.1080/07357900500283101
Scott GB, Carter C, Parrish C, Wood PM, Cook G. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy. Cell Immunol. 2015;297:1–9. https://doi.org/10.1016/j.cellimm.2015.05.002 .
doi: 10.1016/j.cellimm.2015.05.002
pubmed: 26051632
Hanashima Y, Sano E, Sumi K, Ozawa Y, Yagi C, Tatsuoka J, et al. Antitumor effect of lenalidomide in malignant glioma cell lines. Oncol Rep. 2020;43:1580–90. https://doi.org/10.3892/or.2020.7543 .
doi: 10.3892/or.2020.7543
pubmed: 32323826
pmcid: 7108053
Martinez-Høyer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol. 2020;91:22–31. https://doi.org/10.1016/j.exphem.2020.09.196 .
doi: 10.1016/j.exphem.2020.09.196
pubmed: 32976949
Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer. 2009;101:803–12. https://doi.org/10.1038/sj.bjc.6605206 .
doi: 10.1038/sj.bjc.6605206
pubmed: 19638977
pmcid: 2736839
Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, et al. Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. J Transl Med. 2016;14:119. https://doi.org/10.1186/s12967-016-0872-2 .
doi: 10.1186/s12967-016-0872-2
pubmed: 27149858
pmcid: 4857418
Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, et al. A phase I trial to evaluate antibody-dependent cellular cytotoxicity of cetuximab and lenalidomide in advanced colorectal and head and neck cancer. Mol Cancer Ther. 2016;15:2244–50. https://doi.org/10.1158/1535-7163.MCT-15-0879 .
doi: 10.1158/1535-7163.MCT-15-0879
pubmed: 27458141
pmcid: 6805142
Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, et al. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016;77:1097–102. https://doi.org/10.1007/s00280-016-3000-3 .
doi: 10.1007/s00280-016-3000-3
pubmed: 27085994
Said R, Ye Y, Hong DS, Naing A, Falchook G, Fu S, et al. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 2016;77:575–81. https://doi.org/10.1007/s00280-015-2952-z .
doi: 10.1007/s00280-015-2952-z
pubmed: 26825327
Zuo W, Zhu X, Yang J, Mei Z, Deng M, Lin Q, et al. Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: a case report. Medicine (Baltimore). 2017;96: e5787. https://doi.org/10.1097/MD.0000000000005787 .
doi: 10.1097/MD.0000000000005787
pubmed: 28072730
Saleem K, Franz J, Klem ML, Yabes JG, Boyiadzis M, Jones JR, et al. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol. 2022;9:e906–18. https://doi.org/10.1016/S2352-3026(22)00289-7 .
doi: 10.1016/S2352-3026(22)00289-7
pubmed: 36354020
Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7:12050. https://doi.org/10.1038/ncomms12050 .
doi: 10.1038/ncomms12050
pubmed: 27363682
pmcid: 4932178
Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 first trial of up-front treatment for multiple myeloma. Blood. 2018;131:301–10. https://doi.org/10.1182/blood-2017-07-795047 .
doi: 10.1182/blood-2017-07-795047
pubmed: 29150421
pmcid: 5774211
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57–73. https://doi.org/10.1016/S1470-2045(18)30687-9 .
doi: 10.1016/S1470-2045(18)30687-9
pubmed: 30559051
pmcid: 6318225
Ujiie N, Enomoto Y, Takido N, Kawaharada Y, Zuguchi M, Kubota Y. Rapid progression of gastric cancer with liver metastasis after discontinuation of lenalidomide in a patient with concurrent multiple myeloma: a case report. Int J Surg Case Rep. 2021;81: 105834. https://doi.org/10.1016/j.ijscr.2021.105834 .
doi: 10.1016/j.ijscr.2021.105834
pubmed: 33887857
pmcid: 8050724